California Public Employees Retirement System Sells 5,505 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX)

California Public Employees Retirement System lessened its holdings in shares of Mirati Therapeutics, Inc. (NASDAQ:MRTXGet Rating) by 6.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 73,925 shares of the biotechnology company’s stock after selling 5,505 shares during the period. California Public Employees Retirement System’s holdings in Mirati Therapeutics were worth $4,963,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Signaturefd LLC grew its holdings in shares of Mirati Therapeutics by 102.4% during the first quarter. Signaturefd LLC now owns 338 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 171 shares during the last quarter. Treasurer of the State of North Carolina boosted its holdings in Mirati Therapeutics by 1.6% in the first quarter. Treasurer of the State of North Carolina now owns 15,427 shares of the biotechnology company’s stock valued at $1,268,000 after acquiring an additional 248 shares during the last quarter. First Horizon Advisors Inc. bought a new position in Mirati Therapeutics in the second quarter valued at about $25,000. Advisor Group Holdings Inc. boosted its holdings in Mirati Therapeutics by 211.1% in the first quarter. Advisor Group Holdings Inc. now owns 644 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 437 shares during the last quarter. Finally, IndexIQ Advisors LLC bought a new position in Mirati Therapeutics in the first quarter valued at about $42,000.

Mirati Therapeutics Stock Up 11.3 %

MRTX stock opened at $95.85 on Friday. The business has a 50 day moving average price of $70.07 and a two-hundred day moving average price of $67.95. The company has a market cap of $5.52 billion, a price-to-earnings ratio of -7.16 and a beta of 0.84. Mirati Therapeutics, Inc. has a twelve month low of $32.96 and a twelve month high of $154.17.

Wall Street Analysts Forecast Growth

MRTX has been the topic of several recent research reports. SVB Leerink decreased their price target on Mirati Therapeutics from $111.00 to $102.00 and set an “outperform” rating on the stock in a report on Wednesday, November 9th. Citigroup decreased their price target on Mirati Therapeutics from $127.00 to $121.00 and set a “buy” rating on the stock in a report on Wednesday, November 16th. JPMorgan Chase & Co. decreased their price target on Mirati Therapeutics from $109.00 to $94.00 and set an “overweight” rating on the stock in a report on Monday, September 26th. B. Riley began coverage on Mirati Therapeutics in a research note on Friday, October 28th. They issued a “neutral” rating and a $72.00 target price on the stock. Finally, StockNews.com began coverage on Mirati Therapeutics in a research note on Wednesday, October 12th. They issued a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.64.

Mirati Therapeutics Profile

(Get Rating)

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.

Read More

Want to see what other hedge funds are holding MRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirati Therapeutics, Inc. (NASDAQ:MRTXGet Rating).

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.